Abstract #4058

Longitudinal Changes in Magnetic Resonance Spectroscopy Over 96 Weeks in Relapsing MS Treated with Ocrelizumab versus Interferon Beta-1a

Erin L MacMillan¹, Julia J Schubert¹, Irene M Vavasour^1,2, Roger Tam², Alexander Rauscher², Rick White³, Hideki Garren⁴, David Clayton⁴, Victoria Levesque⁴, David KB Li², Anthony L Traboulsee¹, and Shannon H Kolind¹

¹Neurology, University of British Columbia, Vancouver, BC, Canada, ²Radiology, University of British Columbia, Vancouver, BC, Canada, ³Statistics, University of British Columbia, Vancouver, BC, Canada, ⁴Genetech, Roche Pharmaceuticals, South San Francisco, CA, United States

Single voxel magnetic resonance spectroscopy (MRS) was performed in thirty-seven relapsing multiple sclerosis (MS) patients, who were enrolled in a phase III clinical trial of ocrelizumab versus interferon beta-1a, at baseline, 24, 48, and 96 weeks follow-up. 24 healthy controls were also scanned. MRS demonstrated a significant interaction between visit and treatment group in the NAA/tCr ratio. The change in absolute metabolite concentrations over 96 weeks revealed that this interaction was primarily driven by increased NAA and reduced inflammation in the ocrelizumab group, while the interferon beta-1a group exhibited a smaller increase in NAA and ongoing inflammation.

How to access this content:

For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.

After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.

After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.

Click here for more information on becoming a member.